Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Chinese Patent Office
UBS
Accenture
Covington
Merck
Colorcon
Cerilliant
Julphar
Mallinckrodt

Generated: October 21, 2017

DrugPatentWatch Database Preview

Sentynl Theraps Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SENTYNL THERAPS INC, and what generic alternatives to SENTYNL THERAPS INC drugs are available?

SENTYNL THERAPS INC has two approved drugs.

There are three US patents protecting SENTYNL THERAPS INC drugs.

There are ninety-three patent family members on SENTYNL THERAPS INC drugs in twenty-eight countries and fifteen supplementary protection certificates in six countries.

Summary for Applicant: Sentynl Theraps Inc

International Patents:93
US Patents:3
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-001Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-001Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-006Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-002Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
LEVORPHANOL TARTRATE
levorphanol tartrate
TABLET;ORAL074278-001Mar 31, 2000RXNoYes► Subscribe► Subscribe► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-005Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-003Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-001Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-003Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-005Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SENTYNL THERAPS INC drugs

Drugname Dosage Strength Tradename Submissiondate
fentanyl citrate
Sublingual Tablets0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg
ABSTRAL
6/19/2014

Non-Orange Book Patents for Sentynl Theraps Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,454,996Pharmaceutical composition for the treatment of acute disorders► Subscribe
8,512,747Pharmaceutical composition for the treatment of acute disorders► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sentynl Theraps Inc Drugs

Country Document Number Estimated Expiration
European Patent Office1652518► Subscribe
European Patent Office1115383► Subscribe
Denmark2236133► Subscribe
Estonia200700030► Subscribe
New Zealand510646► Subscribe
Sweden9803240► Subscribe
Poland347467► Subscribe
Hong Kong1091722► Subscribe
Luxembourg92636► Subscribe
China1328448► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sentynl Theraps Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00522Netherlands► SubscribePRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
00523Netherlands► SubscribePRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
2014 00016Denmark► SubscribePRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831
4Finland► Subscribe
2011000009Germany► SubscribePRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
C/GB06/022United Kingdom► SubscribePRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
2015 00004Denmark► SubscribePRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
2015000006Germany► SubscribePRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
00714Netherlands► SubscribePRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2014000024Germany► SubscribePRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Mallinckrodt
Johnson and Johnson
Cantor Fitzgerald
Farmers Insurance
US Department of Justice
Boehringer Ingelheim
Daiichi Sankyo
Federal Trade Commission
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot